Trinity Biotech Secures $7.0 Million Investment from Perceptive Advisors and Regains Nasdaq Compliance
核心洞察
Trinity Biotech secured approximately $7.0 million in additional investment from funds managed by Perceptive Advisors (搜索), its largest financial investor and primary lender.
The funding comprises roughly $2.5 million of new debt and $4.5 million of capitalised interest under an amendment to existing financing arrangements.
Trinity Biotech regained compliance with Nasdaq's minimum bid price requirement, with its ADS closing at $1.00 or greater for 10 consecutive business days.
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes (搜索) management solutions, announced on August 14, 2026 that it secured approximately $7.0 million in additional investment from funds managed by Perceptive Advisors (搜索), a leading life sciences investment firm and Trinity Biotech's largest financial investor and primary lender. The company simultaneously announced that it has regained compliance with Nasdaq's minimum bid price requirement.
The total investment of $7.0 million comprises approximately $2.5 million of new debt funding and approximately $4.5 million of capitalised interest under an amendment to the company's existing financing arrangements. The latest investment builds on Perceptive Advisors (搜索)' longstanding support of Trinity Biotech, strengthening the company's liquidity and financial flexibility as it continues to execute its strategic priorities.
Strategic Priorities and Business Transformation
The additional capital is intended to further support strategic growth initiatives, including advancing the CGM+ continuous glucose monitoring platform, pursuing opportunities across the company's diagnostics and metabolic health businesses, and developing innovative liquid cooling solutions for AI data centre infrastructure through its Trinovium subsidiary.
John Gillard, Chief Executive Officer of Trinity Biotech, commented: "Perceptive's additional investment and the restoration of our compliance with Nasdaq's minimum bid price requirement, represent important positive developments for Trinity Biotech. Perceptive has been a highly supportive investment partner throughout our transformation. We believe this further investment reflects confidence in the strategic direction of the company and the exciting opportunities ahead of us."
Gillard added: "Taken together, these developments further strengthen the platform from which we are advancing key strategic initiatives including CGM+ and Trinovium while continuing to build value across our broader diagnostics portfolio."
Nasdaq Compliance Restored
Trinity Biotech announced that on August 7, 2026, it received confirmation from The Nasdaq Stock Market LLC that the company had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). For 10 consecutive business days, from July 24, 2026 through August 6, 2026, the closing bid price of the company's American Depositary Shares (ADSs) was $1.00 per share or greater.
Financial Performance and Strategic Repositioning
Preliminary revenues for the quarter ended June 30, 2026 were approximately $10.5 million, broadly consistent with revenues for the quarter ended March 31, 2026, as the company continues to focus on the finalisation of its operational transformation.
Trinity Biotech continues to advance its strategic repositioning, which is now in the latter stages. This repositioning reflects both structural changes in global healthcare markets and management's assessment of the long-term opportunities created by advances in sensor technology, artificial intelligence and digitally delivered healthcare. As part of this strategy, the company continues to explore technology acquisitions and strategic partnerships with companies engaged in the development of human diagnostics and diabetes (搜索) management solutions, including products that complement Trinity Biotech's CGM+ wearable biosensor product that is under development.
About Trinity Biotech
Trinity Biotech plc is a commercial-stage biotechnology company focused on human diagnostics and diabetes (搜索) management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments of the diagnostic market, and has recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc. Through its Trinovium subsidiary, Trinity Biotech is extending its fluid manufacturing and analytical capabilities into advanced liquid cooling solutions for AI data centre infrastructure. Trinity Biotech sells directly in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.